论文部分内容阅读
本文用单向免疫扩散法比较了104例健康人和22例泡球蚴患者用丙硫咪唑治疗前和治疗期间的血清IgG、IgA和IgM水平。结果表明:治疗前和治疗期间,泡球蚴患者血清IgG和IgM水平均非常显著地高于健康人,但从治疗18个月后,P值由<0.01转为<0.05,而IgA水平呈上下波动。在用丙硫咪唑治疗1～3月期间,泡球蚴患者血清IgG水平升高,随后稳定下降,而IgM和IgA水平于整个治疗期间均处于波动状态。IgG-ELISA抗体滴度在治疗1个月时即明显下降,此后持续下降但呈上下波动。血清IgG浓度与IgG-ELISA抗体滴度间在治疗10～12个月以后有相关(r各为0.68,0.54,0.75,P<0.05～P<0.02),而IgA和IgM和IgG-ELISA抗体滴度间均无相关。
One-way immunodiffusion was used to compare serum IgG, IgA and IgM levels before and during treatment with alzheimer in 104 healthy individuals and 22 patients with metacercariae. The results showed that serum IgG and IgM levels were significantly higher in patients with metacercariae before and during treatment than those in healthy people, but P value increased from <0.01 to <0.05 after 18 months, fluctuation. Serum IgG levels were increased in patients with metacercariae during the course of 1 to 3 months of treatment with albendazole, and then decreased steadily, whereas levels of IgM and IgA fluctuated during the entire treatment period. IgG-ELISA antibody titers dropped significantly at 1 month of treatment, but continued to decline but fluctuated. Serum IgG concentration and IgG-ELISA antibody titers were correlated between 10 and 12 months after treatment (r = 0.68,0.54,0.75, P <0.05 to P <0.02), while IgA and IgM and IgG-ELISA antibody titers There is no correlation between degrees.